

RECEIVED
CENTRAL FAX CENTER

MAR 25 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

PATENT
Attorney Docket No.: 15270J-4729US
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Christopher B.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

**For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE**

Examiner: **Laurie Scheiner**

Art Unit: **1648**

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 10/816,529 Issued as U.S. Patent No. 6,818,218 (the "218 PATENT")